Minimal Residual Disease-based Strategy with T-Cell Redirector After Treatment with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma
NCT ID: NCT06353022
Last Updated: 2025-03-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
103 participants
INTERVENTIONAL
2024-06-26
2030-06-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The patient population will consist of adults men and women at least 18 years to younger than 66 years of age, who meet eligibility criteria.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT03763162
A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma
NCT06577025
A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma
NCT03234972
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma
NCT05257083
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
NCT04923893
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Teclistamab and Lenalidomide
Patients treated with Teclistamab and Lenalidomide for finite duration.
Teclistamab
Maintenance therapy wtih teclistamab (administered via SC injections) for finite duration. Teclistamab will be used in 28 day cycles following initial step up doses
Lenalidomide
Induction therapy with lenalidomide:
Lenalidomide 25 mg/day oral from Day 1 to Day 21.
Maintenance therapy lenalidomide (administered orally) for finite duration.
Bortezomib
Induction therapy with Borthezomib Cycle 1 to 6: Bortezomib 1.3 mg/m² SC twice a week on Days 1, 4, 8 and 11
Daratumumab
Induction therapy with Daratumumab Cycle 1 to 6 Daratumumab 1800 mg SC on Days 1, 8, 15, 22 of Cycle 1 and Cycle 2 and on Days 1 and 15 of Cycle 3
Dexamethasone
Induction therapy with Dexamethasone:
cycle 1 to 3 Dexamethasone 40 mg/day oral or IV on Days 1, 8, 15, 22 Cycle 4 to 6 --\> Dexamethasone 40 mg/day oral or IV on Days 1, 8, 15, 22
Talquetamab andTeclistamab
Patients treated with Teclistamab and Talquetamab for finite duration
Teclistamab
Maintenance therapy wtih teclistamab (administered via SC injections) for finite duration. Teclistamab will be used in 28 day cycles following initial step up doses
Talquetamab
Maintenance therapy with talquetamab (administered via SC injections) for finite duration. Talquetamab will be used in 28 day cycles following initial step up doses
Lenalidomide
Induction therapy with lenalidomide:
Lenalidomide 25 mg/day oral from Day 1 to Day 21.
Maintenance therapy lenalidomide (administered orally) for finite duration.
Bortezomib
Induction therapy with Borthezomib Cycle 1 to 6: Bortezomib 1.3 mg/m² SC twice a week on Days 1, 4, 8 and 11
Daratumumab
Induction therapy with Daratumumab Cycle 1 to 6 Daratumumab 1800 mg SC on Days 1, 8, 15, 22 of Cycle 1 and Cycle 2 and on Days 1 and 15 of Cycle 3
Dexamethasone
Induction therapy with Dexamethasone:
cycle 1 to 3 Dexamethasone 40 mg/day oral or IV on Days 1, 8, 15, 22 Cycle 4 to 6 --\> Dexamethasone 40 mg/day oral or IV on Days 1, 8, 15, 22
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Teclistamab
Maintenance therapy wtih teclistamab (administered via SC injections) for finite duration. Teclistamab will be used in 28 day cycles following initial step up doses
Talquetamab
Maintenance therapy with talquetamab (administered via SC injections) for finite duration. Talquetamab will be used in 28 day cycles following initial step up doses
Lenalidomide
Induction therapy with lenalidomide:
Lenalidomide 25 mg/day oral from Day 1 to Day 21.
Maintenance therapy lenalidomide (administered orally) for finite duration.
Bortezomib
Induction therapy with Borthezomib Cycle 1 to 6: Bortezomib 1.3 mg/m² SC twice a week on Days 1, 4, 8 and 11
Daratumumab
Induction therapy with Daratumumab Cycle 1 to 6 Daratumumab 1800 mg SC on Days 1, 8, 15, 22 of Cycle 1 and Cycle 2 and on Days 1 and 15 of Cycle 3
Dexamethasone
Induction therapy with Dexamethasone:
cycle 1 to 3 Dexamethasone 40 mg/day oral or IV on Days 1, 8, 15, 22 Cycle 4 to 6 --\> Dexamethasone 40 mg/day oral or IV on Days 1, 8, 15, 22
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Age, Type of Patient, Disease Characteristics
1. Male or female patients must be at least 18 years of age at the time of consent younger than 66 years.
2. Documented multiple myeloma satisfying the calcium elevation, renal insufficiency, anemia, and bone lesions (CRAB) criteria and measurable disease (Source: Rajkumar 2014)
3. Newly diagnosed patients eligible for high dose therapy and autologous Stem cell therapy.
4. Have a Karnofsky performance status score ≥50% (Eastern Cooperative Oncology Group ECOG performance status ECOG score ≤2.
5. Have clinical laboratory values meeting the following criteria.
Sex and Contraceptive/Barrier Requirements
6. A female patient of childbearing potential must have a negative serum pregnancy test within 10 to 14 days prior to the start of study treatment and again either a serum or urine pregnancy test within 24 hours of the start of study treatment and must agree to further serum or urine pregnancy tests during the study and for a period of 6 months after the last dose of study treatments.
7. A female patient must be :
1. Not of childbearing potential, or
2. Of childbearing potential and 1) Practicing 2 reliable methods of contraception simultaneously including one highly effective method of contraception and one other effective method of contraception starting 4 weeks prior to dosing, throughout the study including during dose interruptions and for period of 6 months after the last dose of study treatments. For patients who are of childbearing potential.
8. A female patient must agree not to donate eggs or freeze for future use, for the purposes of assisted reproduction during the study and for a period of 6 months after the last dose of other study treatments. Female patients should consider preservation of eggs prior to study treatment as anti-cancer treatments may impair fertility.
9. A male patient must wear a condom (with spermicidal foam/gel/film/cream/suppository) when engaging in any activity that allows for passage of ejaculate to another person during the study and for a period of 6 months after the last dose of study treatments. If the male patient's partner is a female of childbearing potential, she must also be practicing a highly effective method of contraception.
10. A male patient must agree not to donate sperm for the purpose of reproduction during the study and for a period of 6 months after receiving the last dose of study. Male patients should consider preservation of sperm prior to study treatment as anti cancer treatments may impair fertility.
Informed Consent
11. Voluntary written informed consent must be given before performance of any study related procedure not part of normal medical care, with the understanding that the patient may withdraw consent at any time without prejudice to future medical care.
12. Willing and able to adhere to the lifestyle restrictions specified in this protocol.
13. Affiliation with French social security system or beneficiary from such system.
Medical Conditions
1. Peripheral neuropathy or neuropathic pain Grade 2 or higher, as defined by the NCI CTCAE Version 5.0.
2. Chronic Obstructive Pulmonary Disease (COPD) with a Forced Expiratory Volume 1 (FEV1) \<50% of predicted normal. Note that FEV1 testing is required for patients with known or suspected of having COPD or asthma and patients must be excluded if FEV1 \<50% of predicted normal.
3. Moderate or severe persistent asthma within the past 2 years, uncontrolled asthma of any classification. Note that FEV1 testing is required for patients known or suspected asthma and patients must be excluded if FEV1 \<50% of predicted normal.
4. Central Nervous System (CNS) involvement or clinical signs of meningeal involvement of multiple myeloma. If either is suspected, negative whole brain MRI and lumbar cytology are required.
5. Plasma cell leukemia, Waldenström's macroglobulinemia, polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes (POEMS) syndrome (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes), or primary light chain amyloidosis.
6. Any ongoing myelodysplastic syndrome or B cell malignancy (other than multiple myeloma).
7. Any history of malignancy, other than multiple myeloma, which is considered at high risk of recurrence requiring systemic therapy.
8. Active malignancies other than multiple myeloma. The only allowed exceptions are malignancies treated within the last 24 months that are considered cured:
1. Non-muscle invasive bladder cancer.
2. Non-melanoma skin cancers treated with curative therapy or localized melanoma treated with curative surgical resection alone
3. Noninvasive cervical cancer
4. Localized prostate cancer with a Gleason Score ≤7a, treated locally only
5. Breast cancer: adequately treated lobular carcinoma in situ or ductal carcinoma in situ, or history of localized breast cancer
6. Other malignancy that is considered cured with minimal risk of recurrence in consultation with the Sponsor
9. Stroke, transient ischemic attack, or seizure within 6 months prior to signing informed consent form.
10. Presence of the following cardiac conditions:
1. New York Heart Association stage III or IV congestive heart failure
2. Myocardial infarction or coronary artery bypass graft ≤6 months prior to enrollment
3. History of clinically significant ventricular arrhythmia or unexplained syncope, not believed to be vasovagal in nature or due to dehydration
4. Uncontrolled cardiac arrhythmia or clinically significant ECG (Electrocardiogram) abnormalities
5. History of severe non-ischemic cardiomyopathy
11. Concurrent medical or psychiatric condition or disease that is likely to interfere with study procedures or results, or that in the opinion of the investigator would constitute a hazard for participating in this study, such as:
1. Acute diffuse infiltrative pulmonary disease
2. Evidence of active systemic viral, fungal, or bacterial infection, requiring systemic antimicrobial therapy
3. History of autoimmune disease with the exception of vitiligo, type I diabetes, and prior autoimmune thyroiditis that is currently euthyroid based on clinical symptoms and laboratory testing.
4. Disabling psychiatric conditions, severe dementia, or altered mental status.
5. Any other issue that would impair the ability of the patient to receive or tolerate the planned treatment at the investigational site, to understand informed consent or any condition for which, in the opinion of the investigator, participation would not be in the best interest of the patient or that could prevent, limit, or confound the protocol- specified assessments.
6. History of noncompliance with recommended medical treatments
12. Contraindications or life-threatening allergies, hypersensitivity, or intolerance to any study drug (daratumumab, bortezomib, lenalidomide, dexamethasone, teclistamab or talquetamab) or its excipients or analogues and study-required co-medication.
13. Incidence of gastrointestinal disease that may significantly alter the absorption of oral drugs.
Prior/Concomitant Therapy
14. Prior or current systemic therapy or SCT for any plasma cell dyscrasia, with the exception of emergency use of a short course of corticosteroids before treatment.
15. Received a strong CYP3A4 inducer within 5 half-lives prior to the first dose of study treatment (Flockhart 2016: http://medicine.iupui.edu/flockhart/).
16. Plasmapheresis within 28 days prior to the first dose of study treatment.
17. Patient had major surgery or had significant traumatic injury within 2 weeks prior to the start of administration of study treatment, or will not have fully recovered from surgery, or has major surgery planned during the time the patient is expected to be treated in the study or within 2 weeks after administration of the last dose of study treatment.
18. Taken any disallowed therapies, Concomitant Therapy before the planned first dose of study intervention.
19. Received a live, attenuated vaccine within 4 weeks before the first dose of study drug. Non-live or replicating vaccines authorized for emergency use (eg, COVID-19) are allowed.
Diagnostic Assessments
20. HIV infection (positive, history, treatment for HIV).
21. Hepatitis B infection (ie, HBsAg or HBV-DNA positive). In the event the infection status is unclear, quantitative viral levels are necessary to determine the infection status.
22. Active hepatitis C infection as measured by positive HCV-RNA testing. Patients with a history of HCV antibody positivity must undergo HCV RNA testing. If a patient with history of chronic hepatitis C infection (defined as both HCV antibody and HCV RNA positive) completed antiviral therapy and has undetectable HCV-RNA 12 weeks following the completion of therapy, the patient is eligible for the study.
Other non-inclusions
23. Patients unable to complete baseline next generation sequencing (NGS) evaluation at Screening.
24. Patient is pregnant, a nursing mother, or planning to become pregnant while enrolled in this study or within 6 months after the last dose of study treatment.
25. Patient plans to father a child while enrolled in this study or within 6 months after the last dose of study treatment, whichever is later.
26. Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the patient or that could prevent, limit, or confound the protocol-specified assessments.
27. Person under guardianship, trusteeship or deprived of freedom by a judicial or administrative decision.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Janssen Pharmaceutica
INDUSTRY
Nantes University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CH de la Côte Basque
Bayonne, , France
CHU Caen
Caen, , France
CHRU DIjon
Dijon, , France
Chd Vendee
La Roche-sur-Yon, , France
CHRU LILLE - Hôpital Claude Huriez
Lille, , France
CHU Limoges
Limoges, , France
CH Lyon Sud
Lyon, , France
IPC Marseille Institut Paoli Calmettes
Marseille, , France
CHU Montpellier
Montpellier, , France
CHU de Nantes
Nantes, , France
APHP Hôpital Saint Louis
Paris, , France
APHP Hôpital Saint-Antoine
Paris, , France
APHP Hôpital La Pitié Salpétrière
Paris, , France
CHU BORDEAUX - Hôpital du Haut Lévêque
Pessac, , France
CHU Poitiers
Poitiers, , France
CHRU Rennes - Hôpital de Pontchaillou
Rennes, , France
ICANS Institut de Cancérologie Strasbourg Europe
Strasbourg, , France
CHU Toulouse
Toulouse, , France
CHU Tours Hôpital Bretonneau
Tours, , France
CHRU Nancy - Hôpitaux de Brabois
Vandœuvre-lès-Nancy, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-508310-41
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
RC23_0267
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.